What Bio-Techne's Quarter ended Sep 30, 2026 10-Q says: 2 signals
Bio-Techne filed its latest 10-Q with the SEC on Nov 6, 2026. It discusses acquisition announced and margin pressure.
Public (TECH)Biotechnology Research5,001 to 10,000 employeesbio-techne.comLinkedIn
Get Bio-Techne's live signals in Claude or ChatGPT, or by API
What changed at Bio-Techne this week? Use Autobound signals for bio-techne.com.- Filed
- Nov 6, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 7
Source: Autobound Signal API · 80 signals tracked for Bio-Techne · updated
10-Q · latest 7
What Bio-Techne's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 2 signals
Merck KGaA acquisition of Bio-Techne approved by shareholders, expected closing late 2026/early 2027
Bio-Techne shareholders voted on September 23, 2026 to approve the merger agreement under which Merck KGaA will acquire the company.
Diagnostics and Spatial Biology segment operating margin declines to 7.4% from 11.2%
Operating margin for the Diagnostics and Spatial Biology segment fell from 11.2% in the prior year period to 7.4% for the quarter ended September 30, 2026.
7.4%
operating margin for the Diagnostics and Spatial Biology segment
- SEC EDGAR
10-Q · Quarter ended Mar 31, 2026
Filed · 3 signals
Consolidated gross margins fell to 66.9% from 67.9% due to changes in product mix
Consolidated GAAP gross margins dropped to 66.9% for the quarter ended March 31, 2026, compared to 67.9% in the prior year period, primarily driven by product mix fluctuations.
66.9%
consolidated gross margin for the quarter ended March 31, 2026
Bio-Techne executes restructuring and facility consolidations across operating segments
Bio-Techne is actively managing ongoing profitability and cost reduction initiatives, incurring restructuring costs of $2.95 million for the quarter and $14.20 million for the nine months ended March 31, 2026, which include activities like consolidating facilities and reducing overhead.
$14.2M
restructuring and restructuring-related costs incurred for the nine months ended March 31, 2026
Diagnostics and Spatial Biology operating margin benefited from Exosome Diagnostics divestiture
Bio-Techne reported operating margin improvements in its Diagnostics and Spatial Biology segment driven in part by the Exosome Diagnostics divestiture.
- SEC EDGAR
10-Q · Quarter ended Dec 31, 2025
Filed · 2 signals
Adjusted gross margin compressed from 70.5% to 68.5% driven by product mix
Bio-Techne reported consolidated adjusted gross margin declined to 68.5% from 70.5% for the quarter ended December 31, 2025, primarily resulting from changes in product mix.
68.5%
adjusted gross margin for the quarter ended December 31, 2025
Bio-Techne completed the divestiture of Exosome Diagnostics, which favorably impacted the operating margin of the Diagnostics and Spatial Biology segment.
$4.6M
proceeds received for assets held-for-sale
Earnings calls
Bio-Techne earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Emerging biotech sales down high single digits on funding lagRevenues from emerging biotech customers dropped high single digits in Q3 following historical funding constraints. Despite recent rebounds in late-stage funding, early-stage discovery budgets remain suppressed, impacting core reagent demand. Management does not anticipate a meaningful recovery until the first half of fiscal 2027. | |
| Brand realignment streamlines 10 product brands down to 3In April, the company executed a portfolio brand alignment consolidating 10 brands into three: R&D Systems, Bio-Techne Spatial Biology, and Bio-Techne Diagnostics. This strategy aims to simplify customer engagement and workflow integration across research and clinical applications. It also enhances product discoverability across digital and AI-driven platforms. | |
| Spatial Biology grew mid-teens with COMET up over 65%The Spatial Biology portfolio delivered mid-teens revenue growth, powered by more than 65% expansion in the COMET Multiomic Spatial platform. The franchise exited the quarter with another record backlog for COMET and installed its first unit in China, while RNAscope kits achieved high single-digit growth. Sellers targeting lab automation, imaging, or pathology reagent supply chains will find... | |
| Steve Crouse promoted to President of Diagnostics and Spatial BiologySteve Crouse was appointed President of the Diagnostics and Spatial Biology segment after leading the Analytical Solutions unit for five years. Leadership changes often trigger vendor and operational process evaluations within the division. The segment reported $85.6 million in quarterly revenue, up 3% organically. | |
| Adjusted gross margin down 120 bps from unfavorable mixAdjusted gross margin contracted year-over-year to 70.4% from 71.6% due to negative product mix. Adjusted operating margin dropped 70 basis points year-over-year to 34.2% as a result of mix and volume deleverage. Operating margins partially offset the decline through structural streamlining and the Exosome Diagnostics divestiture. | |
| Collaboration with Providence Health and Microsoft on GigaTIME AIThe company highlighted a research collaboration with Providence Health and Microsoft utilizing datasets generated on the COMET spatial biology platform. The joint framework converts traditional H&E pathology images into virtual 3D tissue representations. Management views content-rich biological data as an essential requirement for training healthcare AI models. |
Signal API · MCP
Track Bio-Techne with the Signal API
One POST /v1/companies/enrich call with bio-techne.com returns Bio-Techne 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bio-techne.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Bio-Techne 10-Q
When did Bio-Techne file its latest 10-Q?
What did Bio-Techne disclose in its latest 10-Q?
What did Bio-Techne say on its recent earnings calls?
Where can I read Bio-Techne's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .